Clinical Research Studies

This study will have two groups of patients to test the combination of AMG 510 (Sotorasib) and panitumumab for advanced cancers with KRAS G12C mutations. Group 1 is a randomized phase II trial for patients with advanced solid tumors (except lung and colorectal cancer) who haven’t had treatment with a KRAS G12C inhibitor before. Patients will be randomly assigned to either AMG 510 alone or AMG 510 combined with panitumumab, with AMG 510 given at 960 mg once a day and panitumumab at 6 mg/kg every two weeks. Group 2 is for patients who have already used a KRAS G12C inhibitor and had their cancer progress. Patients in this group can have any type of tumor, including lung or colon cancer. Treatment will continue until the cancer grows or the side effects become too severe, and tumors will be checked every 8 weeks. The main goal of the study is to measure how well the treatment works by looking at the response rate.